BiotechTube

Capsaicin 8% + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Peripheral Neuropathy

Conditions

Diabetic Peripheral Neuropathy, Pain

Trial Timeline

Feb 1, 2012 → Feb 1, 2014

NCT ID
NCT01533428

About Capsaicin 8% + Placebo

Capsaicin 8% + Placebo is a phase 3 stage product being developed by Astellas Pharma for Diabetic Peripheral Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01533428. Target conditions include Diabetic Peripheral Neuropathy, Pain.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01533428Phase 3Completed

Competing Products

20 competing products in Diabetic Peripheral Neuropathy

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
44
CHF6467 activeComac MedicalPhase 1/2
33
Ruboxistaurin mesylateEli LillyPhase 3
77
KVD001 InjectionKalVista PharmaceuticalsPhase 2
47
KVD001 InjectionKalVista PharmaceuticalsPhase 1
28
Baricitinib + PlaceboEli LillyPhase 2
52
LY3857210 + PlaceboEli LillyPhase 2
52
UBX1325Unity BiotechnologyPhase 2
44
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
44
UBX1325Unity BiotechnologyPhase 1
25
CT-P42 + EyleaCelltrionPhase 3
77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
85
Anplag(Sarpogrelate) + PlaceboYuhanApproved
85
CS-3150 + placeboDaiichi SankyoPhase 2
52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
52
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
77
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-5565Daiichi SankyoPhase 3
77
Beraprost sodiumAstellas PharmaPre-clinical
23

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85